Isis Pharma To Substantially Exceed Year-end Cash Guidance - Quick Facts

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) announced that the company expects to significantly improve upon its 2014 financial guidance. The company expects to end 2014 with a pro forma net operating loss (NOL) in the mid to high teens and more than $725 million in cash.

Elizabeth Hougen, CFO at Isis Pharmaceuticals, said: "Because of our strong financial performance throughout the year, we expect to end 2014 with more than $725 million in cash, substantially exceeding our year-end cash guidance by more than $150 million. We also expect to end 2014 with a pro forma NOL in the mid to high teens, which represents a nearly 70% improvement over our original guidance of a pro forma NOL in the low $50 million range."